OP06 A single centre retrospective analysis of new patients presented to the hepatology clinic with non-alcoholic fatty liver disease post-covid era

BackgroundNon-alcoholic fatty liver (NAFLD) is a common condition and occurs in 25% of the population. It is associated with other metabolic risk factors as in diabetes, hypertension, obesity and dyslipidaemia. The treatment is focused on optimising metabolic risk factors. Most of the targeted treatment for NAFLD are ongoing.Aims and MethodsThe aim of the retrospective study to understand the cohort of NAFLD patients who were referred to the hepatology clinic between September 2020 and May 2022. We reviewed the demographics, the underlying metabolic risk factors as well as the non-invasive fibrosis assessment of the cohort.ResultsDuring the study period, 134 patients were seen. The majority was female (54%); from white ethnicity (82%) with mean age of 55 years (range 17–87). Three people died during the study period and two died from decompensated liver cirrhosis.Most patients are obese (71%) with mean body mass index (BMI) of 34.88 kg/m2 (range: 21.5–59.3) with most of them in WHO Obese type 2 category (n=59; 46%).Type 2 diabetes mellitus (T2DM) was seen in 42% and the mean HbA1c was 47 mmol/mol. Most patients were treated (87%) and the majority of them were on metformin (69%). Most required more than 2 medications (44%).Fifty-five patients (40%) had hypertension and 81% were on treatment. The two commonly used medications for hypertension were angiotensin-converting enzyme (ACE) inhibitors and seen in 51%; followed by calcium channel blockers (47%). Around 30% of patients required more than 2 medications to control high blood pressure.Dyslipidaemia was seen in 48% of patients and was treated in 88% of patients. The most common medication used was statin (90%); mostly atorvastatin. In 17% of the population, they had all 3 features of metabolic risk factors (diabetes, hypertension and dyslipidaemia) and all were in overweight and obese category.Fatty liver was reported radio-logically in 72% of the cases. 13% of patients had diagnosis of cirrhosis from imaging. In 59% of patients, patients had Transient Elastography or TE (n=79/134) and among them, 23% had median elastography between 9 and 14.9 kPa and 22% had median elastography above 15 kPa. Abstract OP06 Table 1 Demographics of patients Valid (n=) Missing (n=) Mean Std. Deviation Minimum Maximum Age (years) 134 0 55.522 15.111 17 87 Metabolic risk factors BMI in kg/m2 129 5 34.875 7.168 21.5 59.3 HbA1c (mmol/mol) 118 16 47.398 14.793 27 94 Total cholesterol (mmol/L) 119 15 4.646 1.195 1.9 7.4 Triglyceri